Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
they have hired -gs-/and -cs- to valuate their company
to come up with a fair price. i think after valuation,
the bid will increase. between now and then, the market
price will fluctuate.
Where did you get that 14.50 from?
So were at 14.50 but its my opinion GSK ups offer to 16.00 bucks
Congratulations longs. Glx buyout bid out this am.
'HGSI' - (DJ Glaxo Launches Hostile Bid For Human Genome Sciences)
DOW JONES NEWSWIRES
GlaxoSmithKline PLC (GSK) has made an unsolicited takeover bid for U.S.-based Human Genome Sciences Inc. (HGSI), the target company said Thursday.
HGS said the U.K. pharmaceutical giant is offering $13.00 a share in cash, valuing it at over $2.5 billion--a price that the target company said is inadequate. HGS shares closed at $7.17 on Wednesday.
"The HGS board of directors, in consultation with independent financial and legal advisors, has carefully reviewed and considered the Glaxo offer and has determined that the offer does not reflect the value inherent in HGS," it said in a statement.
HGS also said its board has authorized the exploration of "strategic alternatives," which could include a potential sale.
A Glaxo spokeswoman said Thursday the company is planning to issue a release.
Glaxo has long been considered a potential suitor for HGS, with which it has a close relationship.
The companies have a partnership agreement on Benlysta, a treatment for lupus, under which they share profits. The drug is expected to become HGS's main revenue driver.
HGS is also co-developing two other compounds with Glaxo: darapladib, for the treatment of heart disease; and albiglutide, for diabetes. Both are in late-stage testing.
The U.S. company said it has requested additional information regarding those products in Glaxo's pipeline to which HSG has financial rights, including darapladib and albiglutide.
HGS also said it hired Goldman Sachs and Credit Suisse to assist.
At 1028 GMT, Glaxo shares were up 17 pence, or 1.2%, at 1459 pence, on a slightly higher FTSE 100 index.
5 Biotech Stocks Ready To Rise On New Treatments
April 18, 2012
I believe one of the keys to smart biotech investing is to focus on companies that are treating chronic diseases. Instead of looking to cure something, the treatments developed and marketed by these companies will help patients manage symptoms. This ensures long-term success and allows you to invest your money in a company that is protecting its own security. There are five standout companies in the biotech industry that I consider the best bets for those who want a long term, steady earner.
The first company I have been watching for awhile is Human Genome Sciences (HGSI). The company is poised to make a big splash in 2012, due to its focus on treatments that will affect the baby boomer generation. The company reached a 52-week high of $30 per share at one point, but plummeted to just $6 per share in the last year. The price is currently around $7. HGSI released Benlysta in 2011, a treatment for adult patients with active systemic lupus who are currently receiving standard therapy. Benlysta was the first drug approved to treat lupus in more than 50 years and I believe it will bring steady earnings in the upcoming months. Lupus is a chronic disease, so Benlysta sales are predicted to be steady.
In addition to Benlysta, HGSI, in conjunction with GlaxoSmithKline (GSK), reported successful results from phase 3 trials of a drug intended to treat Type 2 diabetes. An April news release provided more information about the testing, showing seven of its eight Harmony Phase III trials as successful.
_________________________________________________
http://seekingalpha.com/article/506001-5-biotech-stocks-ready-to-rise-on-new-treatments
HGSI
Human Genome Sciences Could Jump Higher On Darapladib, Strong Pipeline
April 18, 2012
There are a lot of investors and analysts worried about Human Genome Sciences (HGSI) these days, but I think the company is going to be just fine. There are three reasons why I would still put money into HGSI, especially at around the going rate of $7.
First, the company is still going strong with its on-the-market drug. I always consider a company with an approved, marketed drug a great investment when the price is this low. Second, the competition in this price range has a different focus than HGSI. Finally, HGSI has a strong pipeline that I believe will turn it into a major contender in the coming years.
Even analysts who do not agree with my short-term outlook for HGSI have not written it off down the road. Patient investors should see a buy into HGSI pay off big in the long run.
The great thing about a long-term outlook on biotech stocks is that your entire existence is not predicated on FDA approval. HGSI investors will watch the FDA, of course, but a single negative announcement will not be a make or break scenario for the company. For starters, HGSI is incredibly affordable at the moment. It dropped steadily through 2011 and the first part of 2012, and most investors began to write it off as over with. The conclusions were hasty and I would consider now the best time to make a bid.
One of the biggest reasons is HGSI's drug Benlysta. It was approved in 2011, becoming the first lupus medication to be approved by the FDA in more than 50 years. As a side note, HGSI is also responsible for Raxibacumab, a treatment for inhalation anthrax. Obviously not all that commercially successful, the medication is sold to the government as part of its Strategic National Stockpile. This is good to know and it provides some security, but more of my focus is on Benlysta and the other promising components of HGSI.
One of the main reasons HGSI saw a price reduction with the approval of Benlysta is because it still owns the drug independently. Many drug developers have begun selling off products once the treatment receives approval. This avoids expensive marketing costs, but makes the company a one-time profit or provides ongoing royalty payments. HGSI is taking on more of the responsibility and cost of managing Benlysta, but it stands to earn steadily over the years because it is the only one making a profit from the drug. The drug did not sell as well as expected in 2011, but that is not to say it was not successful. Expectations were very high and now that the market has a better idea of what to expect, things can settle down. HGSI has also made a concerted effort to educate doctors about the product and the education efforts appear to be paying off. HGSI predicts a strong 2012, primarily based on the efforts it has made to market and educate Benlysta.
Perhaps of even more interest to investors is HGSI's stability. The company is in good financial shape, even though it has significant overhead from its full ownership of its products. It reported over $881 million in cash in 2011 and $562 million in convertible debt, due to mature in mid-November 2018 with an interest rate of 3%.
I divide my evaluation of HGSI's competition into two categories. The first is other companies focused on lupus treatment. In at least one case, the price for a competitor is so much higher than HGSI, it would hardly be a consideration at the moment. Eli Lilly (LLY) is in phase three trials of its lupus treatment that should be competed in early 2014. ImmuPharma (LMM) also has a lupus drug in phase three trials, which has received a fast-track from the FDA and has received special protocol assessment, meaning it is highly likely to be approved.
Obviously these developments could cause a threat to Benlysta, but there is enough time to position Benlysta solidly in the medical industry before there is a problem. ImmuPharma is going for more than the equivalent of $100 on the London Stock Exchange and Eli Lilly, one of the nation's drug development giants, clocks in around $40 at the moment. Investors expecting to pay less than $10 a share will not consider either of these an option. I would keep my eye on the companies strictly for what is being accomplished in regard to specific treatments and how these treatments will affect Benlysta.
The second category of comparison is biotech stock in the same price range. Three competitors that are in the same price range are Spectrum (SPPI), Achillion (ACHN), and Idenix (IDIX). Each focuses on different treatments, so there is no direct competition in regard to lupus treatment. Spectrum is developing cancer treatments and has primarily an oncology focus. Achillion has programs focused on HCV treatments and Idenix has its hands in HCV, as well as HIV and hepatitis B. These companies are in the same price range as HGSI, but none are focused on lupus.
Finally, HGSI has a strong pipeline, which I believe will ultimately keep it earning steadily regardless of the competition Benlysta faces. The company's goals include expanding the usage of Benlysta into other fields, including as a treatment for vasculitis. It is also developing Albiglutide in a partnership with GlaxoSmithKline. The drug is intended to treat diabetes, a market that is growing as fast as any and shows no signs of slowing down. Also in the pipeline is Darapladib, another drug developed with GlaxoSmithKline (GSK), in phase three trials for treating coronary heart disease. Like diabetes, heart disease is forecast to become an even greater problem in the coming years. As a matter of fact, there was a bump in all treatments intended to focus on obesity-related issues recently when a report was issued by the OECD.
Basically, HGSI is playing a role in a variety of different places. In addition to lupus, it intends to become a player in the growing market of treating obesity-related diseases. I believe HGSI is a great investment, especially for patient investors, at its current price, and I would recommend buying as soon as possible.
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
______________________________________________________________
http://seekingalpha.com/article/505441-human-genome-sciences-could-jump-higher-on-darapladib-strong-pipeline
HGSI
"Human Genome Sciences Inc. (NASDAQ: HGSI) Started as Neutral at UBS."
HGSI
Buy Human Genome Sciences: The Long-Term Potential Is Intact
April 11, 2012
The biotechnology sector is one that is filled with much risk, but also much reward. Too often, people see the biotechnology sector as one that exists only for trading around FDA announcements or mergers and acquisitions. But there are biotech companies that present long-term opportunity for patient investors. And we would like to highlight such a company.
Human Genome Sciences (HGSI) is a Maryland-based biotechnology company that has several products on the market, and several in the pipeline. We first recommended Human Genome Sciences on August 29, 2011, at a price of $12.63, calling it a buy for investors with a high-tolerance for risk. Since then, the stock has fallen sharply, as the company failed to meet expectations. But we feel that at current prices, the shares are simply too cheap to ignore. The company's fundamentals have in no way deteriorated as much as the decline in the stock would suggest.
Benlysta (belimumab) is the company's lead drug, and it is an antibody created for the treatment of lupus (systemic lupus erythematosus), and when it was approved in 2011, it became the first new lupus treatment approved by the FDA in 50 years. Human Genome Sciences also sells raxibacumab, an inhalation anthrax treatment, to the American government for use in the Strategic National Stockpile. Before we continue laying out the thesis for Human Genome Sciences, a quick overview of the company is in order.
Overview
Human Genome Sciences has had quite a journey over the past 5 years, as the stock gyrated wildly on hopes for Benlysta's approval and then its commercial potential. In the past 5 years, the stock has traded in a range between almost $33 and under $1.
[img]static.seekingalpha.com/uploads/2012/4/10/1007049-13340823765521832-Helix-Investment-Management_origin.png
[/img]
This chart is revealing for what it does not show, namely a soaring stock in 2011 on the back of Benlysta's approval. We believe that the culprit has been a blend of investor expectations and slower than estimated Benlysta sales.
In the past several years, there has been a new phenomenon developing in the biotechnology sector where companies sell-off once their drugs reach the market, as investors adjust to the realities of actually selling and marketing drugs, as opposed to simply developing them. In addition, the fact that Human Genome Sciences continues to remain an independent company has contributed to its falling stock price. Furthermore, slower than expected Benlysta sales in 2011 have caused the stock to steadily fall.
We believe that sales will be seen as adequate going forward, primarily for 3 reasons. The first is that expectations have been largely reset from 2011 levels, and that several temporary issues affecting physician ability to prescribe Benlysta have been resolved. Second, when Benlysta first came to market, it received a temporary Q-code for insurance reimbursement, as opposed to a permanent J-code (which was received in January).
And third, Human Genome Sciences spent a good deal of 2011 educating physicians on exactly which patients to start with, as the indication for Benlysta is broad. And these efforts appear to be paying off. In reporting its full-year 2011 results, the company noted that its education efforts are gaining traction, and studies commissioned by the company show consistent improvement among lupus patients across a wide spectrum of lupus manifestations.
Investor perception is crucial in investing, and we believe that in the quarters to come, perceptions of Benlysta will improve. The nature of lupus is such that patients do not always need an immediate change in treatment to Benlysta, and the company is working to address those issues. Human Genome Sciences forecasts a better year in 2012 for Benlysta sales. We will now provide a brief overview of Human Genome Sciences' financials.
Financial Overview
As with most biotechnology companies, Human Genome Sciences is in good financial shape, operating losses aside. The company ended 2011 with over $881 million in cash & equivalents. The company has around $562 million in convertible debt as well, and it matures on November 15, 2018 and has an interest rate of 3%. We see no immediate financial pressures on the company, as it has more than enough liquidity to meet its operating needs.
(click to enlarge)
Human Genome Sciences is working hard to rapidly grow revenue. The loss of tens of millions in collaborative revenue [an agreement with Novartis (NVS) over Zalbin] in 2011 has led to increased operating losses, but we believe that in 2012, the impact of that will begin to be dampened, as Benlysta revenue continues to grow. Human Genome Sciences managed to narrow its fourth quarter loss from the previous year.
Human Genome Sciences Financial Overview
Q4 2011 Q4 2010 2011 2010
Product Revenue $39.276 Million $13.196 Million $104.863 Million $47.159 Million
Manufacturing & Development Revenue $5.828 Million $7.517 Million $24.840 Million $22.695 Million
Collaborative Revenue $0.418 Million $0.549 Million $1.272 Million $87.497 Million
Operating Expenses $114.585 Million $97.443 Million $460.526 Million $348.124 Million
Operating Income (Loss) -$69.063 Million -$76.181 Million -$329.551 Million -$190.773 Million
GAAP EPS -$0.41 -$0.46 -$1.97 -$1.24
Human Genome Sciences may have widened its GAAP loss in 2011, but we believe that it will steadily narrow in the years ahead, eventually leading to profitability. Although Benlysta may not have ramped up in 2011 as rapidly as some market observers may have liked, it is growing. Sales were $8 million in Q2 2011, $18 million in Q3 2011, and $26 million in Q4 2011. Profitability is set to be reached by 2014. We now turn to the competition that Human Genome Sciences faces.
Competition
Not every biotechnology company has the luxury of being Alexion Pharmaceuticals (ALXN), which develops orphan drugs for extraordinarily rare diseases, which allows it to sell them free of competition. This is why Alexion's only commercialized drug, Soliris, holds the record for being the world's most expensive drug, at $409,500 per year of treatment. Human Genome Sciences faces competition on several fronts, both for Benlysta and compounds in its pipeline.
2 other companies are working on new lupus treatments. Eli Lilly (LLY) is developing LY2127399, which is in Phase III trials, with an estimated primary completion date of January 2014. In addition, ImmuPharma is developing Lupuzor, and it too is in Phase III trials. All else being equal, we believe that Lupuzor is the bigger threat. It has received fast-track designation from the FDA, and more importantly, it has received a special protocol assessment. This SPA essentially means that should unless there are unforeseen issues, and clinical data from Phase III trials meets certain criteria, Lupuzor will be approved.
Analysts are bullish on ImmuPharma (a British company) and Lupuzor's potential, but also say that Lupuzor is not likely to dethrone Benlysta from its leadership position in the lupus space. Rather, Lupuzor is expected to emerge alongside Benlysta as the new standard of care in the lupus field.
We do not see Human Genome Sciences going the way of Dendreon (DNDN), where its product is marred by controversies over its efficacy in the face of multiple new competitors. Benlysta will be the only available lupus treatment for the next several years, and by the time competitors such as Lupuzor are on the market, we believe that Human Genome Sciences will have diversified its revenue base. To see how the company will accomplish that, we must look at the pipeline.
Pipeline
Human Genome Sciences has several compounds in development, and we detail them below.
Expanding Benlysta usage: Many biotechnology companies use label expansion as a revenue and profitability driver, and this company is no exception. Currently, Benlysta is being researched for applications in vasculititis, with Phase III trials set to commence in the second half of 2012. In addition, Benlysta is being studied in other forms of lupus, specifically active lupus nephritis, with Phase III trials also set for the second half of 2012
Albiglutide: Albiglutide is Human Genome Science's type 2 diabetes treatment, developed in partnership with GlaxoSmithKline (GSK), and it is currently in Phase III trials. The companies released clinical data on the compound last week, and the compounds Harmony 6 trial showed meaningful reductions in HbA1c and non-inferiority versus insulin. Harmony 8 will be completed at the end of 2012, and five other ongoing studies regarding albiglutide will be completed in 2013. Should Albiglutide be approved for the treatment of diabetes, it will enter a fiercely competitive, albeit large market. Many other companies compete in this space, including Amylin (AMLN), Novo Nordisk (NVO), and Eli Lilly.
Darapladib: This inhibitor, developed with GlaxoSmithKline is in a second Phase III trial for the treatment of coronary heart disease, with acute coronary syndrome (ACS), being a particular focus. Data is likely to be released sometime in 2012 or the first half of 2013.
Mapatumumab: This is a cancer treatment currently in Phase II trials. The cancer sector is extremely competitive, but the potential is enormous, for the addressable market for cancer treatments is extremely large. It is a bit early to gauge the potential of this treatment, but should it successfully navigate into Phase III trials and eventual approval, Mapatumumab could be a profitable drug for Human Genome Sciences.
HGS-1036: This compound was licensed from FivePrime Therapeutics in March 2011, and Phase Ib chemotherapy studies are planned in 2012. It is too early to tell what sort of impact this compound will have.
One thing stands out in this pipeline, and that is the involvement of GlaxoSmithKline. The company is Human Genome Sciences' partner on Benlysta, and is collaborating with it on multiple other compounds. And when a large pharmaceutical company partners with a small biotechnology company, takeover speculation is sure to follow.
GlaxoSmithKline: Deal or no Deal?
Speculation has been rife for years that Glaxo will buy Human Genome Sciences. The rumor is brought up often. As recently as October, it was reported that GlaxoSmithKline was prepared to make a $25 per share offer for the company. While virtually any combination is possible in the biotechnology sector, at this moment in time we do not believe that Glaxo will bid for Human Genome Sciences, and our bullish thesis is not built around such an assumption.
We believe that proof of Glaxo's lack of interest lies in the fact that the company has not already made a move. There are few partnerships as deep as the one between Glaxo and Human Genome Sciences, and the only company to know more about Human Genome Sciences than Glaxo is Human Genome Sciences itself. Therefore, if no deal has been reached as of this point, it is likely that there will be no deal.
So will another pharmaceutical company bid for Human Genome Sciences? At this time, we do not think that will be the case. The reason, in our opinion, stems from the mindset of these other companies. If Glaxo, the outsider that knows the most about Human Genome Sciences does not wish to bid, then why should we? Critics may counter here, arguing that if no one wishes to buy Human Genome Sciences, it must be due to the fact that its drugs are not worth buying. We however, believe that the reason is more complex.
As recently as March 2010, Human Genome Sciences traded in the $30s, and has fallen sharply since those highs. For shareholders who bought the stock then, or have held it for a long time, accepting an offer of even $25 per share would be unpalatable. We believe that the board of Human Genome Sciences knows this. And the board of GlaxoSmithKline knows this. Its own shareholders would likely never approve of a takeover at the premium needed to satisfy Human Genome Sciences shareholders. Therefore, the company is likely to sit out any waves of consolidation in the sector.
Our thesis, however, takes a long-term view of the company, and is predicated on it remaining independent. That being said, we do not see the lack of a takeover as a negative. GlaxoSmithKline has invested huge sums of money in the development and commercialization of Benlysta, as well as the rest of Human Genome Science's pipeline, and we do not think that would happen if Glaxo did not think the drugs have the potential to generate substantial returns on its investment.
We see the endorsement and backing of GlaxoSmithKline as a huge vote of confidence in Human Genome Sciences . And so is the company's shareholder base. From the shareholder base, it is clear that Human Genome Sciences has support. Fidelity and T-Rowe Price together own nearly 28% of the company, and the top 10 institutional investors in Human Genome Sciences own over 60% of the company's shares.
Conclusions
This is not a stock for investors expecting quick profits tomorrow. Nor is it a stock with which to speculate on takeovers in the biotechnology sector. It is a company whose stock has fallen too far in relation to its fundamentals, which are slowly but surely improving. Benlysta is gaining traction, and the pipeline is progressing. The backing of GlaxoSmithKline insulates Human Genome Sciences and provides an endorsement of its therapies.
Even after analysts lowered their expectations due to the launch issues with Benlysta, the Reuters average price target for shares of Human Genome Sciences stands at $13.65, representing upside of 81.27% from current levels. We believe that for patient investors, the stock is trading at an attractive price and that investors who believe in the company's potential will be rewarded greatly for their faith.
Disclosure: I am long HGSI, AMLN, ALXN, DNDN.
Additional disclosure: We are long shares of DNDN via the First Trust NYSE Arca Biotechnology Index Fund.
___________________________________________________
http://seekingalpha.com/article/490271-buy-human-genome-sciences-the-long-term-potential-is-intact
HGSI
Human Genome Sciences: Will A Strong Pipeline Create Profits?
April 9, 2012
For a biotech stock to be a real winner, it takes more than just successful clinical trials and FDA approvals or the potential of a drug in development as a cure for a particular disease. A lot depends on the choice of target market and the demand for effective and safe treatment. For instance, many biotech companies have zeroed in on the baby boomer generation, and their health concerns and treatment requirements are what is catalyzing in the research and development of new drugs and more effective treatment. After all, the 76 million Americans who make up this generation represent a sizable chunk of the market. Regarded in this light, Human Genome Sciences (HGSI) could prove to be a promising investment.
The stock has a 52-week trading range of $6 to $30. The company has a close relationship with GlaxoSmithKline (GSK), which is one of the largest Pharma companies in the world and has financial rights to some GlaxoSmithKline products. While HGSI is not entirely a single product company, I believe that in the near future, the success of Benlysta is going to be critical to the returns that investors would receive. This is an injectable antibiotic treatment for lupus which works by inhibiting the production of a protein called BLyS. Benlysta is the first lupus treatment that has been approved by the FDA in 56 years [in March 2011] and does not have any competitors. It is currently undergoing phase 2 clinical trials for the treatment of vasculitis and patients and for use with patients who have undergone kidney transplants. The company is also researching more effective delivery systems for the product.
The company shares commercial rights with GlaxoSmithKline on Benlysta and the drug definitely has the potential to be a blockbuster and chalk up sales in the region of $1 billion every year. Indeed, many analysts expect 2012 revenues to be in the range of $300 million to $700 million. What sales revenues are actually achieved will determine the revenue growth of HGSI as well as its valuation. In an evolving process, the big Pharma companies have drugs going off patent on a continuous basis and need to acquire affordable companies in order to replace these products. With a market cap of around $10 billion, I believe that HGSI is going to be an affordable acquisition for any major Pharma company all of whom are sitting on mountains of cash. A possible acquisition by GlaxoSmithKline because of the potential of Benlysta is one of the major attractions and holding on to the stock or even acquiring more. I consider the company to be fairly valued at the current stock price.
An area of concern for any investor should be the pricing of Benlysta which could cost up to $35,000 every year and has resulted in doctors not been particularly enthusiastic about prescribing this medication. One of the chief worries is the concern about insurance reimbursement for its considerable expenditure. It is going to take years for HGSI to make money on the drug and I consider it extremely unlikely that it can afford to reduce prices significantly. The drug has been launched in Canada and several European nations such as Germany, Spain, Austria and Denmark and the deception is encouraging though revenue growth is slower than I would have liked to see.
It is time to turn our attention to some of the other pipeline drugs being developed by HGSI. HGSI is developing a drug for type 2 diabetes as part of its relationship with GlaxoSmithKline, and a recent news release has revealed that seven out of eight Harmony Phase 3 Trials have been successful. HGSI used its proprietary albumin-fusion technology to create Albiglutide and licensed it to GlaxoSmithKline in 2004. HGSI will receive payments of almost $200 million when it reaches specified milestones. In addition, if the drug is successful commercially, the company also stands to receive royalties in the single digits on global sales. GlaxoSmithKline has confirmed that it would push ahead with plans for approval and that the drug has not yet been approved for use anywhere in the world. Analysts expect yearly sales to be modest and in the region of about $250 million at the end of the next five years.
In May 2009, HGSI submitted a Biologics License Application [BLA] to the FDA for a pipeline of drug for the treatment of anthrax caused by inhalation and, in November 2009, FDA issued a Complete Response Letter. HGSI is working with the FDA towards approval though the process as always is time consuming and expensive and the outcome is uncertain. Raxibacumab is an injectable treatment that prevents the toxins from the anthrax bacteria from spreading through the body. The treatments presently available can kill the bacteria but are not effective if the toxin has already been released. Some revenue has already been earned from the US government emergency stockpile.
HGSI competes with a few companies which already have products on the market for treating lupus by suppression of the immune system. Biogen Idec (BIIB) produces a treatment for lymphoma called Rituxan, while the Swiss giant Roche (RHHBY.PK) produces CellCept an immune system suppressant. Both Immunopharma and Eli Lilly (LLY) have pipeline drugs in phase 3 trials in Lupuzor and BAFF. However, as I have noted, nothing competes directly with Benlysta and HGSI continues to be in the enviable position of having a monopoly.
No matter what happens, HGSI should continue to develop more successful pipeline drugs in order to continue to be an attractive investment candidate. Having a drug in a monopoly position is definitely worth something, but without translating into substantial sales revenues, the potential in terms of returns to investors is unlikely to be fulfilled. The company is meanwhile burning a lot of cash in pursuit of success but, in my opinion, continues to be fairly valued. I consider it unlikely that GlaxoSmithKline will make any acquisition moves in the current year. My recommendation is to hold if you already have an investment in HGSI, but do not take any new positions at this time.
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
This article was sent to 969 people who get email alerts on HGSI.
_________________________________________________________
http://seekingalpha.com/article/486591-human-genome-sciences-will-a-strong-pipeline-create-profits
HGSI
At 8 bucks HGSI is stock you need to own,Strong buy.see you at 15.00
The Appeal Of Human Genome Sciences While It's Still Under $10
April 4, 2012
The success of a biotech stock is based on much more than just a positive clinical trial or potential cure for disease. As the market grows, the desire for safe, effective treatments also grows. This is why smart investors have their eye on the aging population of the more than 76 million baby boomers in the country. Their health concerns are the driving force behind research and development at many biotech companies. Focusing on the health concerns of this generation helps you make savvy investment decisions. I believe several companies, including Human Genome Sciences (HGSI), is one of the companies poised to make a big splash in 2012, due to its focus on treatments that will affect the baby boomer generation.
The company reached a 52-week high of $30 per share, but plummeted as low as $6 per share in the last year. Just over a year ago, HGSI released Benlysta, a treatment for adult patients with active systemic lupus who are currently receiving standard therapy. Benlysta was the first drug approved to treat lupus in more than 50 years. The company also has financial rights to a number of GlaxoSmithKline (GSK) products. Even with the significant drop in price, HGSI should still be considered a smart investment, particularly because of its relationship with GlaxoSmithKline.
Type 2 Diabetes
In addition to Benlysta, HGSI, in conjunction with GlaxoSmithKline, saw successful results from phase 3 trials of a drug intended to treat Type 2 diabetes. An April 3, 2012 news release provided more information about the phase 3 trials, showing seven of its eight Harmony Phase 3 Trials were successful. Albiglutide was created by HGSI using its proprietary albumin-fusion technology, but was licensed to GlaxoSmithKline in 2004. However, HGSI is entitled to fees and milestone payments that could amount to as much as $183 million, in addition to single-digit net royalties on worldwide sales if Albiglutide is commercialized.
Obesity
With its latest phase 3 trials a success, HGSI is poised to make a big jump, making it a wise investment, especially for those who want to be a part of the biotech stock surge. Pharmaceutical and biotech stock is closely tied to the future of healthcare and the more severe a health crisis there appears to be, the more likely a stock price is to rise.
____________________________________________________
http://seekingalpha.com/article/478301-the-appeal-of-human-genome-sciences-while-it-s-still-under-10
HGSI
Big Pharma Is Desperate for Product and Small Biotech Is the Answer
By Matt Nesto | Breakout – 1 hour 50 minutes ago
If a 30% year-to-date rally in the Biotech industry (BTK) has caught your eye but crimped your courage, it may be time to think again. That's because for all its short-term strength, the sexy corner of the otherwise stodgy Health Care sector (XLV) has really just regained lost ground, when in fact, a new cycle of innovation is just getting underway.
"I think we are beginning to see signs of life amongst biotechs, with new products coming to market that are gaining traction," says Marshall Gordon, health care analyst at Clear Bridge Advisors, a New York based asset manager with $55 billion in assets under management. "Innovation is a great way to get paid, in any market environment or regulatory environment."
Of course, the upside of biotech's innovation is paired with the downside of its legendary volatility, which is an inescapable side-effect for this business, as is the omnipresent opportunity (or threat) of being acquired, since Gordon agrees that every small biotech company is a potential target.
"If you look at the pharmaceutical industry today, they are desperate for products, and the way to get those is by buying biotech," he says.
To that extent, Gordon has flagged three small players that he thinks possess tremendous upside.
(other stock info deleted)
Gordon also owns Human Genome Sciences (HGSI) --an $8 stock that was $30 about a year ago, but like Onyx, is being undervalued. He thinks its new Lupus drug, the first such treatment t0 gain FDA approval in the past 50 years, is bigger than most analysts expect and will deliver better than expected sales once doctors start using and seeing the results firsthand.
_________________________________________________
http://finance.yahoo.com/blogs/breakout/big-pharma-desperate-product-small-biotech-answer-141833680.html
HGSI
7:03AM Human Genome reported that it is entitled to fees and milestone payments that could amount to as much as $183 million from GlaxoSmithKline's (GSK) phase 3 trial for Albiglutide (HGSI) 8.09 : Albiglutide was created by HGSI using its proprietary albumin-fusion technology, and was licensed to GSK in 2004. HGSI is entitled to fees and milestone payments that could amount to as much as $183 mln-- including $33.0 mln received to date -- in addition to single-digit net royalties on worldwide sales if albiglutide is commercialized.
GlaxoSmithKline: Upbeat results on diabetes study
April 3, 2012, 2:17 a.m. EDT
LONDON (MarketWatch) --
GlaxoSmithKline PLC , a research-based pharmaceutical and healthcare company said Tuesday it received topline results from seven of the eight 'Harmony' Phase III studies investigating the use of albiglutide in type 2 diabetes.
MAIN FACTS:
-Albiglutide is an investigational once weekly glucagon-like peptide-1 (GLP-1) agonist.
-In Harmony 6, the second of the phase III 'Harmony' studies to complete, albiglutide was compared to preprandial insulin, each administered on top of long-acting insulin glargine.
-In this study, the first of its kind for the class, albiglutide produced clinically significant reductions in HbA1c from baseline and non-inferiority versus preprandial lispro insulin after 26 weeks of treatment, achieving theprimary endpoint.
-Results showed a reduction in HbA1c from baseline of 0.82% for patients receiving albiglutide compared to a reduction of 0.66% for preprandial lispro insulin.
-The company also announced that 2 year data read-outs from five ongoing phase III studies (Harmony 1 through Harmony 5) have been received.
-These read-outs present the final results for primary endpoint data up to two years. As the five ongoing studies have not completed, these data have to remain confidential to protect the integrity of the ongoing blinded studies and in line with our agreements with regulators.
-Harmony 8 will complete in mid 2012 and the five ongoing studies will complete in early 2013.
-GSK has now reviewed primary endpoint data--6 months to 2 years-- on the efficacy and safety of albiglutide, verses placebo and active controls, across seven Phase III studies.
-GlaxoSmithKline shares closed Monday at GBP14.29, valuing the company at GBP72.06 billion.
________________________________________________
http://www.marketwatch.com/story/glaxosmithkline-upbeat-results-on-diabetes-study-2012-04-03
HGSI
Human Genome (HGSI) Affirms New Albiglutide from Glaxo (GSK)
April 3, 2012 7:46 AM EDT
HGSI Hot Sheet
Overall Analyst Rating:
NEUTRAL (= Flat)
Revenue Growth %: +113.6%
Human Genome (Nasdaq: HGSI) reports that GlaxoSmithKline (NYSE: GSK) issued an update on its Phase III of Albiglutide. For more color, click here.
Albiglutide was created by HGS using its proprietary albumin-fusion technology, and was licensed to GSK in 2004. HGS is entitled to fees and milestone payments that could amount to as much as $183 million – including $33.0 million received to date – in addition to single-digit net royalties on worldwide sales if albiglutide is commercialized.
All inquiries regarding the albiglutide Phase 3 data announced today should be directed to the contacts provided by GSK.
__________________________________________________________
http://www.streetinsider.com/Corporate+News/Human+Genome+(HGSI)+Affirms+New+Albiglutide+from+Glaxo+(GSK)/7317043.html
HGSI
Human Genome (NASDAQ:HGSI) Canaccord Genuity has initiated coverage for Human Genome at Hold. Human Genome Sciences, Inc. is a commercially focused biopharmaceutical company advancing toward the market with three products in late-stage clinical development.
Read more: http://thestockmarketwatch.com/stock-market-news/analyst-ratings/new-analyst-coverage/analysts-initiated-coverage-for-ziop-dndn-fnfg-hmst-hgsi-incy/23514#ixzz1qycZr94A
HGSI
Zacks Reiterates a “Neutral” Rating on Human Genome Sciences (HGSI)
Posted by Tammy Falkenburg on Mar 29th, 2012 // No Comments
Human Genome Sciences (NASDAQ: HGSI)‘s stock had its “neutral” rating reiterated by Zacks in a research note issued on Thursday. They currently have a $8.25 price target on the stock.
Zacks’ analyst wrote, “Human Genome’s fourth quarter 2011 loss of $0.41 per share was narrower than the year-ago loss of $0.46. The loss narrowed due to higher revenues. An encouraging sign for the company was a substantial improvement in net sales of lupus drug Benlysta in its second full quarter on the market. We believe that sales of the drug, which has blockbuster potential, will increase further in the upcoming quarters. The approval of the drug in additional markets such as the EU and Canada is also encouraging. Moreover, Benlysta is under review in many other countries. The company is also making efforts to expand Benlysta’s label as well as develop other pipeline candidates. However, we prefer to remain on the sidelines until we get visibility that the improvement in Benlysta is sustainable. We retain our Neutral stance on the stock with a target price of $8.25.”
A number of other firms have also recently commented on HGSI. Analysts at Canaccord Genuity initiated coverage on shares of Human Genome Sciences in a research note to investors on Monday. They set a “hold” rating and a $10.00 price target on the stock. Separately, analysts at Collins Stewart reiterated a “neutral” rating on shares of Human Genome Sciences in a research note to investors on Wednesday, March 21st. Finally, analysts at Brean Murray reiterated a “hold” rating on shares of Human Genome Sciences in a research note to investors on Tuesday, February 28th.
Human Genome Sciences traded up 0.06% on Thursday, hitting $7.90. Human Genome Sciences has a 1-year low of $6.51 and a 1-year high of $30.15. The stock has a 50-day moving average of $8.32 and a 200-day moving average of $9.42. The company’s market cap is $1.572 billion.
Human Genome Sciences, Inc. (HGS) is a biopharmaceutical company. The Company’s products are BENLYSTA (belimumab) for systemic lupus erythematosus (SLE) and raxibacumab for inhalation anthrax.
_______________________________________________________
http://zolmax.com/zacks-reiterates-a-neutral-rating-on-human-genome-sciences-hgsi/2457/
HGSI
4 Biotech Stocks With Strong Upside Potential
March 27, 2012
The last twelve months have been a rocky ride for Human Genome Sciences (HGSI), once tipped as the bright young things of the Biotechnology industry. Since April 2011, shareholders have seen the value of Human Genome stocks fall from a healthy $30 to just under $8 per share, in a series of hair raising drops, fluctuations and partial recoveries. The darkest days for Human Genome Sciences came in early July 2011, when the stock value fell from around $25 to $15 in just a couple of days, with no subsequent recovery.
In recent days, there seems to be no let up in Human Genome Science's precipitous stock collapse. Between 12th and 21st March 2012, no less than 7.4% of its stock value was lost.
With a wildly erratic 52 week range of $6 to $30, investors may be forgiven for looking askance at a company which once led the field in biotechnology research. On the surface, this is an inexplicable fall from grace. Only in 2009, Human Genome Sciences was pulling in government contracts worth around $207 million for delivery of raxibacumab vaccines to the US Strategic National Stockpile for use against a potential anthrax based terrorist attack. At the same time, it was leading the field in phase 3 clinical trials for darapladib, a revolutionary new treatment for coronary heart disease, and albiglutide, a drug treatment for sufferers of type two diabetes - both commanding very handsome contracts and a secure future for the company's stocks.
So what went wrong? Did Human Genome Sciences overstretch itself? The answer to this question lies with an obscure autoimmune disease called Lupus, a potentially fatal condition that affects over 300,000 men and women in the United States. Prior to 2009, the only relief available to sufferers of Lupus was aspirin, the same prescription that had been available since 1955. This was lacking in many ways, and still led Lupus sufferers to experience chronic kidney and nervous problems, as well as complications during pregnancy.
In its trademark, revolutionary style, Human Genome Sciences pioneered a new drug that was potentially life-changing for sufferers of lupus. The new drug Benlysta, also known as Belimumab or LymphoStat-B, was developed in partnership with GlaxoSmithKline (GSK) and put through clinical trials from July 2009. In March 2011 Benlysta was approved by the US Food and Drug Administration [FDA] for treatment of Lupus patients. I can hardly understate the significance of this breakthrough in treating Lupus, not least due to Benlysta being the first serious development in treatment for the disease in nearly sixty years. The price tag wasn't cheap, with the annual treatment bill for each patient expected to run to $35,000.
Accordingly, the stock value of Human Genome Sciences went through the roof, peaking at around $30 in early April 2011.
However, the root of Human Genome Science's problems lie in shares sold during Benlysta's development period between 11th July, 2009 and 20th November, 2010. The Biotech giant is currently fighting a lawsuit against purchasers of common stock during this class period. Scott & Scott LLP were appointed Lead Counsel for the prosecution on 22 March, 2012.
The pending lawsuit alleges that Human Genome Sciences and some of its directors made omissions and false and misleading claims about the efficacy of its lupus busting wonder drug Benlysta. Riding high among these omissions is the drug's poor success rate among African-American patients who participated in the clinical trials. Not only did patients of African-American descent not respond to treatment from Benlysta, but the trial group also reported increased levels of death, serious infection and non-fatal side effects, such as nausea and increased fatigue.
The lawsuit also alleges that Human Genome Sciences chose not to reveal the alarming link between Benlysta treatment and increased incidences of suicide among patients. During the time the company was allegedly concealing the shortcomings of the clinical trials, they were busy selling shares for between $14 and $15.50. In the class period concerned, Human Genome Sciences sold upwards of 44.5 million stocks to eager Biotech investors, making a very respectable profit of $850 million from the proceeds.
I did not find the market reaction surprising when the allegations of Human genome Sciences' misconduct broke in the press in March 2011. It is fair to say that the bottom fell out of the company's stock value, causing huge losses among the investors who had paid premium rates for stocks during the period of the clinical trials. It is also fair to say there were a lot of angry people wanting to hold the company to account for their losses, not to mention widespread dissatisfaction with the shortcomings of Benlysta among the medical community.
Unaffected by the allegations against Human Genome Sciences, GlaxoSmithKline continues to act as the principle sales agent of Benlysta throughout Europe and Canada, where the drug was approved for use with mild cases of Lupus in April 2011. In the last twelve months, GlaxoSmithKline's stock value has increased steadily, and at the time of writing, shares stand at around $46 and rising.
With the lucky exception of GlaxoSmithKline, the Benlysta scandal appears to have had a knock on effect in the wider biotechnology market, with share prices falling for big player Therevance (THRX) in the year from April 2011 and Volcano (VOLC) experiencing a serious dip during the same period before staging a recent recovery. However, this could have been a lot worse, and investor confidence has remained strong in some sectors of the biotech market. Halozyme Therapeutics (HALO), for instance, has experienced no knock on effects from the misfortune of its competitor, and may even have benefited from investment from disillusioned biotech shareholders who fled from Human Genome Sciences when the scandal broke. Halozyme has enjoyed a huge leap in stock value since October 2011. With a 52 week range of $5.50 to $12, shares now stand at over $12.
Although the Benlysta scandal has shaken the confidence of the market and a lot will still hinge on the outcome of the upcoming lawsuit, much of the uncertainty will hopefully have been resolved by the time Human Genome Sciences' directors face a major shareholder meeting in Gaithersburg, MD on 16th May 2012.
With new treatments still rolling out of the laboratories at a furious rate, investors still have every reason to have faith in the biotech industry, and to vote with their wallets.
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
This article was sent to 863 people who get email alerts on HGSI.
__________________________________________________________
http://seekingalpha.com/article/461531-4-biotech-stocks-with-strong-upside-potential
HGSI
Hopefully some good news coming, check the 8 buck calls,33k open interest.
form t trade @ 4:19:33 of 113,900 shares @ $8.132. What is that about? Not the usual t trade.
HGSI
VFC's Take: Is HGSI Still A Decent Pick When Not Factoring In The Buyout Potential?
Posted by Posted by VFC on Mar 26, 2012
"VFC's Take" is a forum where readers can comment or add to ongoing discussions regarding events or companies covered by VFC's Stock House. Remember, you don't have to agree with VFC to contribute - the best discussions are the ones where all angles are covered. All comments are welcome via email: vfc@vfcsstockhouse.com, Twitter (@VFCsStockHouse), Facebook or the VFC's Stock House Seeking Alpha page.
A question from Mark regarding Human Genome Sciences (HGSI) and the potential of the company if we take a potential buyout from the equation:
I wonder if you still have any warm feelings for the stock [HGSI] if it is not a prospect for takeover.
VFC's Take: When Human Genome Sciences received approval for the lupus-treating drug Benlysta just over a year ago, many predicted that the new drug would become an instant blockbuster, given that it was the first new lupus drug to be granted approval by the FDA in over a half century. It also helped that HGSI already had a powerhouse partner on board with GlaxoSmithKline (GSK) to lead the commercialization and marketing strategy.
Benlysta was slow to gain sales momentum on the market, however, so after seeing shares of HGSI soar to thirty dollars on hype and speculation, they quickly fell to the current levels of eight bucks and below.
That said, the Glaxo buyout rumors are brought up enough to lead to some short term spikes, and some believe that the share price won't fall too far below the current levels because of the persistent buyout potential that needs to be priced in, even with Benlysta struggling.
It's my opinion that one should never buy into a stock based on buyout potential alone. Such speculation will be thrown out there time and time again and most of the time a deal never materializes. If a company has a solid enough foundation to where one considers it a solid short or long term investment, then any buyout talk should be taken as icing on the cake, as a bonus, but it should never be the sole reason for buying in, in my opinion.
In the case of Human Genome, there's always a chance that Glaxo will finally step in for a buyout. It makes sense with the existing partnership, but up until this point the rumors and headlines have been used to spark mini-runs in the share price and have not amounted to anything tangible. If a buyout happens, I think it would happen when the share price is depressed and no one is paying attention.
So back to the original question, do I like HGSI when not factoring in the buyout potential?
I do, as a long term investment that gives Doctors time to become convinced that Benlysta works, since many still consider this a 'trial period' for the drug, as described in the company's most recent earnings report. Being the only approved lupus treatment in over fifty years also comes with its detriments. There's a reason why drug companies are not vigorously testing new lupus treating drugs, and there's a reason why there have been no approvals in so long - lupus is such a mysterious ailment that many of the big boys in the pharmaceutical industry do not see dollar signs or good risk/reward when considering new treatments and many medical professionals are still unconvinced that we are near a cure - hence this trial period of convincing.
Once (if), after the 'trial period' for Doctors is completed and they are convinced of the benefits of Benlysta, then the drug could move forward to its blockbuster potential. That's what an investment in HGSI is all about. While the bonus buyout rumors or a surprise spike in sales could lead to some short term upside movement, it's also smart to respect the prospects of short term downside, too.
The company currently trades with a market cap of one point five billion - when earnings are a mere fraction of that cap. If a market correction takes place, or if investors become unconvinced that Benlysta still has its blockbuster potential, then a decline in the HGSI share price could come pretty quick.
On the other hand, the lower the price goes, the better deal it looks like for a potential buyer, which again adds the buyout factor to the equation.
Right now I'd expect volatility until we know one way or another if Doctors believe that Benlysta is the real deal. That makes HGSI a long term patience play, with potential short term catalysts (to the up and downside) also in the mix.
When discussing the long term, however, also consider the rest of the HGSI pipeline.
Disclosure: Long HGSI. Opinions of VFC's Stock House are not intended to be construed as investment advice. Each investors should conduct his or her own DD and/or consult a personal Financial Advisors for any invsting advice.
Contact VFC's Stock House: vfc@vfcsstockhouse.com
Originally published at: http://vfcsstockhouse.com
Follow VFC's Stock House on Twitter: https://twitter.com/#!/VFCsStockHouse
'Like' VFC's Stock House on Facebook: http://www.facebook.com/pages/VFCs-Stock-House/143724412345213
_____________________________________________________
http://vfcsstockhouse.com/blog/article/-vfc-s-take-is-hgsi-still-a-decent-pick-when-not-factoring-in-the-buyout-potential-
HGSI
HUMAN GENOME SCIENCES (HGSI)
NEW SURVEY REVEALS LUPUS COMMUNICATION GAP AS MANY PATIENTS REMAIN SILENT ON TRUE IMPACT OF DISEASE
03/20/2012 | 01:58pm
ROCKVILLE, Maryland, and RESEARCH TRIANGLE PARK, NC - March 20, 2012 -
Results of a new Roper survey of the lupus community released today highlight a communication gap between people with systemic lupus erythematosus (SLE, lupus) and the people who care for and about them. The Roper survey was designed to evaluate the daily and long-term impact of lupus on health, family relationships, career and quality of life, and identify potential gaps in communication.
The results of the national survey were drawn from more than 950 people in the lupus community- 502 people who reported being diagnosed with SLE, 204 supporters (family members or friends) of people with lupus and 251 rheumatologists-and found that patients often downplay their pain and other symptoms. Eighty-seven percent of people with lupus said they downplay symptoms to avoid upsetting their families, and 52 percent reported that they minimize their symptoms to their physician. Yet, 72 percent of physicians surveyed said they were not aware of patients minimizing their symptoms. This difference in perceptions may lead to increased difficulty in managing the complexities of lupus. Adding to this communications gap, almost half (48%) of patients say they have difficulty describing their symptoms to their physician.
"This survey highlights some of the challenges I see in my clinic every day," said Joan Merrill, M.D., chair of the Clinical Pharmacology Research Program at Oklahoma Medical Research Foundation, a leading national lupus center. "I worry about the patients who may have trouble starting a candid conversation with me about how lupus is affecting them and their families. The more we know, the more we may be able to help," she added.
Lupus can affect almost every part of the body and can cause extreme fatigue, painful and swollen joints, unexplained fever, and skin rash. It also can lead to kidney failure, heart and lung inflammation, central nervous system abnormalities, inflammation of the blood vessels and blood disorders, all these symptoms can flare unpredictably and often are invisible to others.
Many people with lupus say they are affected by symptoms nearly every day, and the frequency of these symptoms is sometimes underestimated by others. For example, 51 percent of patients surveyed reported arthritis/joint pain as the most prevalent symptom they experienced every day. However, when doctors were asked to rank the top three most common problems associated with lupus, only 35 percent selected arthritis as the most commonly reported daily symptom.
Lupus can impact more than a person's health. Eighty-one percent of patients surveyed compared lupus with being on a rollercoaster, as they never know what to expect. Seven out of 10 patients (68 percent) said lupus affects virtually every relationship they have, and a similar number (74 percent) of lupus supporters said the same. Interestingly, while supporters take the word "support" to heart-with nearly eight in 10 (78 percent) describing themselves as very supportive-only half (52 percent) of patients say their family and friends are very supportive, and only 34 percent of doctors perceive a patient's family and friends as "very supportive."
Despite patients and their supporters agreeing on the level of impact lupus can have on relationships, many patients said they felt their family and friends did not understand the disease's true burden.
Three-fourths (75 percent) of patients said they felt their family and friends overestimated what they can do. Further, 67 percent of patients said that their family and friends believe they have become unmotivated due to lupus.
Lupus patients, their doctors and their supporters agreed on the need for more resources and a stronger, more connected lupus community:
87 percent of patients and 95 percent of supporters said they wished there were more resources available to help handle issues faced by patients.
54 percent of doctors were frustrated by the limited resources available to educate patients.
34 percent of patients did not think that there was a community available where lupus patients had a voice and could be heard.
"This survey indicates that there is a real problem with communication, but this is also an opportunity to improve the dialogue within the lupus community," Dr. Merrill said. "People may struggle if they feel isolated and lack a sufficient support network. Rethinking the dynamics of our relationships with people who have a chronic illness can be empowering for all of us."
About the National Burden of Lupus Survey
The survey was conducted by Gfk Roper Public Affairs and Communications (GfK Roper North America or Roper) from July through September 2011. It involved 502 people who self reported that they had received a diagnosis of lupus, 204 supporters of people with lupus and 251 rheumatologists (physicians who specialize in treating lupus). The survey was funded and developed by Human Genome Sciences and GlaxoSmithKline.
Resources
People with lupus and those who care for them can visit www.usinlupus.com for online support, information and inspiration. For additional information on lupus, visit the Lupus Foundation of America at www.lupus.org, the Lupus Research Institute at www.lupusresearchinstitute.org, and the National Institute of Arthritis and Musculoskeletal and Skin Diseases at www.niams.nih.gov. Except for usinlupus.com, the websites listed are external to Human Genome Sciences and GlaxoSmithKline. Human Genome Sciences and GlaxoSmithKline do not have control over the content of the information provided on these websites and therefore do not warrant their accuracy or completeness.
###
For more information about Human Genome Sciences (HGS), please visit the company's website at www.hgsi.com. For more information on GlaxoSmithKline, please visit www.gsk.com.
About GfK Roper Public Affairs & Corporate Communications
GfK Roper Public Affairs & Corporate Communications is a division of GfK Custom Research North America. The group specializes in customized public affairs and public opinion polling, media and corporate communications research, and corporate reputation measurement in the United States and globally. In addition to delivering a broad range of customized research studies, GfK Roper Public Affairs & Corporate Communications draws from GfK's syndicated consumer tracking services, GfK Roper Reports® US and GfK Roper Reports® Worldwide, which monitor consumer values, beliefs, attitudes and behaviors in the United States and more than 25 other countries. The division also serves as the official polling partner of the Associated Press conducting the AP-GfK Poll (www.ap-gfkpoll.com).
Inquiries:
Diana Torres
(212) 819-4895
_____________________________________________
http://www.4-traders.com/HUMAN-GENOME-SCIENCES-9544/news/HUMAN-GENOME-SCIENCES-NEW-SURVEY-REVEALS-LUPUS-COMMUNICATION-GAP-AS-MANY-PATIENTS-REMAIN-SILENT-ON-14227929/
HGSI
HEART DISEASE
In the area of heart disease, Cytori is sponsoring three European clinical trials that evaluate the use of adipose-derived stem and regenerative cells (ADRCs) to treat acute myocardial infarction (heart attack) and chronic myocardial ischemia (a severe form of coronary artery disease).
Heart disease is the number one cause of death in the U.S., Europe, and the majority of other countries around the world. Advanced heart disease also accounts for many disabilities, lost productivity, and diminished lifestyle. Cytori performed pre-clinical (in the laboratory) studies that suggested a restoration of heart function following the application of adipose-derived stem and regenerative cells (ADRCs). Cytori is conducting two safety and feasibility trials, the APOLLO and PRECISE trials, in the areas of acute heart attack and chronic myocardial ischemia, respectively. Currently, Cytori is enrolling a pivotal European trial, ADVANCE, for acute myocardial infarction.
ADVANCE
Acute Myocardial Infarction (Europe)
>>Learn more on ClinicalTrials.gov
http://www.clinicaltrials.gov/ct2/show/NCT01216995?term=ADVANCE%20Cytori&rank=1
There are 30mm short,this could explode at anytime just like last month,it went from 7 to 10....strong day today...glty.
"On revised forward P/E analysis, we trim our target price to $13." Still a respectable gain from here. Doing nicely today. Seems to have bottomed out. A steady march up the charts would be fine.
HGSI
« Stock News Overview : ArticleS&P MAINTAINS BUY OPINION ON SHARES OF HUMAN GENOME SCIENCES
2 hours 56 minutes ago - Standard & Poor's
Q4 net loss of $0.41, vs. $0.46, is $0.01 wider than our loss view. Benlysta sales of $25.7M is in line with HGSI's pre-announcement. Although we see limited visibility into Benlysta sales ramp trajectory, we are encouraged by report of positive physician feedback on drug and by HGSI re-affirming profitability target for '14. We expect Benlysta use to expand over time amid lack of lupus options. On narrower Benlysta sales outlook, we widen our '12 loss estimate $0.11 to $1.38, and set '13's at $0.92 loss. On revised forward P/E analysis, we trim our target price to $13.
HGSI is priced right for gains,see you guys over 10 soon and with buy outs in the sector heating up,hgsi could be a morning halt and major gapper anytime.IMO
Re-initiating Credit Coverage on Human Genome Sciences
by Morningstar Credit Committee | 13 Mar 12
Note: This article is taken from Morningstar's U.S.-based Website, www.morningstar.com. All figures are in U.S. dollars.
After incorporating our new take on the slow demand associated with Human Genome Science's HGSI new lupus drug, Benlysta, we are re-initiating our credit rating for the firm at B-. The firm appears to need external financing within the next couple years, and our B- credit rating reflects our belief that the firm will be able to access additional funds by issuing new equity or debt before potentially running out of cash. We could also see some organizational changes; for example, the firm may restructure operations or agree to merge in order to stave off a liquidity crunch. A key merger candidate would be Benlysta's marketing partner, GlaxoSmithKline GSK . However, if demand for Benlysta remains slow and management doesn't act nimbly enough to refinance or reorganize, Human Genome could face bankruptcy with no cushion for debtholders within the next couple years. Therefore, investors should proceed with extreme caution. We will keep our B- credit rating for Human Genome on a very short leash.
The firm's financial position appears precarious. At the end of 2011, Human Genome held $801 million in unrestricted cash and marketable securities compared with $702 million in debt principal outstanding. However, the firm is still bleeding cash. We don't worry about the firm's ability to repay its 2012 convertible debt issue. However, beyond that, continued slow uptake of Benlysta could force Human Genome to need external financing. While we remain optimistic about the lupus drug, any way we slice it, Human Genome Sciences remains speculative, and its road to success or failure may be quite bumpy because it is paved with the prospects of only one product. In this case, we believe that drug's future remains promising. However, if the firm cannot cut its cash burn rate or access external financing sources, debtholders may be left holding worthless paper in a couple years.
________________________________________________________
http://torontostar.morningstar.ca/globalhome/industry/news.asp?articleid=540536
HGSI
Agree. Short interest according to ShortSqeeze:
http://shortsqueeze.com/shortinterest/stock/HGSI.htm
HGSI
I like the risk reward here and i do think at some point a big player buys out hgsi.I'm building a position and hope it goes to the 6.50s so i can by another 3rd of a position.HGSI is just loaded with shorts, 30% of the float i believe is short. Also building a position in Cosi,seems like a good turnaround story.Strong buy
Joined you. The chart looks as if it is ready to recover:
HGSI - Daily Candlesticks
http://torontostar.morningstar.ca/globalhome/industry/news.asp?articleid=540536
HGSI
New 13G filed,TAUBE HODSON STONEX Partners ups holding to over 5.14%
From 7,774,453 to 10,237,263
http://www.nasdaq.com/symbol/hgsi/sec-filings
This was trading at .60 cents and traded as high as 30 dollars?
HGSI is priced right to make money.Big pharma gonna get em at some point.Strong buy IMO
I got my fingers crossed, lol
Starting a position in HDSI today.Been waiting for the 7s, very good risk reward.I do believe HGSI will be bought in the near future.
Human Genome calls active on renewed takeover chatter
http://www.theflyonthewall.com/permalinks/entry.php/HGSI;GSKid1128254
HGSI- GSK PIPELINE: INITIAL RESULTS OF PHASE 3 TRIALS OF ALBIGLUTIDE FOR TYPE 2 DIABETES EXPECTED MID-2012; ENROLLMENT COMPLETED IN SECOND PHASE 3 TRIAL OF DARAPLADIB FOR CARDIOVASCULAR DISEASE
GSK’s Phase 3 program to evaluate the long-term efficacy, safety and tolerability of albiglutide as monotherapy and add-on therapy for patients with type 2 diabetes mellitus continues to move forward. GSK announced topline results of the first of eight Phase 3 trials in November 2011. The study, known as Harmony 7, was designed to compare once-weekly albiglutide to once-a-day liraglutide. Results showed a reduction in HbA1c from baseline of 0.78% for patients receiving albiglutide compared to a reduction of 0.99% for liraglutide. Although the pre-specified margin of non-inferiority to liraglutide was not met, albiglutide did show a statistically significant reduction in HbA1c from baseline (p<0.001). The most common adverse events observed during this study were nausea (9.9% for abiglutide versus 29.2% for liraglutide) and vomiting (5%for abiglutide versus 9.3% for liraglutide).
GSK’s conclusion after review of the data is that the data support continued progress toward registration as a possible once-weekly treatment for type 2 diabetes. GSK expects initial results from the remaining studies over the course of the next several months, and has stated that it expects to provide an update on albiglutide once a more complete view of the data is available in mid-2012
http://www.hgsi.com/latest/human-genome-sciences-reports-progress-with-commercialization-of-benlysta-and-announces-2012-goals-at-jpmorgan-healthcare-confe.html
http://www.gsk-clinicalstudyregister.com/protocol_comp_list.jsp?compound=Darapladib
~ Monday! $HGSI ~ Earnings posted, pending or coming soon! In Charts and Links Below!
~ $HGSI ~ Earnings expected on Monday *
Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.
http://stockcharts.com/h-sc/ui?s=HGSI&p=D&b=3&g=0&id=p88783918276&a=237480049
http://stockcharts.com/h-sc/ui?s=HGSI&p=W&b=3&g=0&id=p54550695994
~ Google Finance: http://www.google.com/finance?q=HGSI
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=HGSI#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=HGSI+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=HGSI
Finviz: http://finviz.com/quote.ashx?t=HGSI
~ BusyStock: http://busystock.com/i.php?s=HGSI&v=2
<<<<<< http://www.earningswhispers.com/stocks.asp?symbol=HGSI >>>>>>
http://investorshub.advfn.com/boards/post_prvt.aspx?user=251916
*If the earnings date is in error please ignore error. I do my best.
Strong pipeline and has been gaining steadily. Good luck if you want to short IMO.
Quite a pb Tues.. I wonder how HGSI will do in this sideways market.
I can't see any reason to not short this.
comments?
Taking off. Any more thoughts beside hang on.
We broke the 10.51 resistance level!
North from here shorts better cover!
Yeah no doubt I added more today.
Were looking good HGSI is getting some legs!
Trading Higher on Heavy Volume are Shares of Human Genome Sciences on 1.6x Above-Average Volume (HGSI)
6 hours 32 minutes ago - F82
Financial News Network Online - Unusual VolumeThe price of Human Genome Sciences shares has climbed to $9.67 (a 5.9% change) on heavy trading volume. Approximately 9.8 million shares have changed hands today vs. average 30-day volume of 6.2 million shares. Spikes in volume can validate a breakout or signify a potential turning point. Human Genome Sciences, Inc. researches and develops proprietary pharmaceutical and diagnostic products. The Company's products predict, prevent, detect, treat, and cure disease based on the discovery of human and microbial genes. Human Genome Sciences has overhead space with shares priced $9.67, or 49.9% below the average consensus analyst price target of $19.31. Human Genome Sciences shares should encounter resistance at the 200-day moving average (MA) of $16.79 and support at the 50-day MA of $7.84. Over the past year, Human Genome Sciences has traded in a range of $6.51 to $30.15 and is now at $9.67, 49% above that low. The 200-day and 50-day moving averages have moved 1.64% lower and 0.49% lower over the past week, respectively. --------------------------------------------------------------------------------------------- Financial News Network Online (FNNO) is a leading provider of digital financial news content for distribution on the web. You can count on FNNO to bring you the latest market news, earnings reports, analyst comments, economic data reports and more. Visit http://www.fnno.com today.
Yeah strong buys and lots of volume.
I agree 100%
Followers
|
21
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
636
|
Created
|
06/06/06
|
Type
|
Free
|
Moderators |
July 20, 2009 3:31 PM ET
Human Genome Sciences (NASDAQ:HGSI) is a biopharmaceutical company with a pipeline of novel protein and antibody drugs directed toward large markets that have significant unmet medical need.
HGS Home page:
HUMAN GENOME SCIENCES AND NOVOZYMES ANNOUNCE AMENDMENT TO ALBUMIN FUSION LICENSE AGREEMENT |
Rockville, Maryland and Nottingham, UK - May 7, 2009 - Human Genome Sciences, Inc. (NASDAQ: HGSI) and Novozymes Biopharma, a part of Novozymes (NASDAQ: NZYM B), today announced that they have amended an existing license agreement to allow both companies to expand application of their proprietary albumin fusion technology. Under the amended agreement, HGS and Novozymes each has the opportunity to exclusively license and/or sublicense a number of albumin fusion proteins in exchange for royalties and other consideration. No existing HGS or Novozymes products or product rights, including rights licensed to other companies, are affected by these amendments. Financial or other terms of the agreement were not disclosed. "Genetic fusion of therapeutic proteins to albumin can improve the pharmacology of the proteins, resulting in important benefits to patients," said Barry A. Labinger, Executive Vice President and Chief Commercial Officer, HGS. "For example, with certain therapeutic proteins, albumin fusion may make it possible to dose less frequently and reduce side effects associated with injections. We are pleased to work with Novozymes to broaden the application of albumin fusion technology to new classes of proteins and peptides." Thomas Videbæk, Executive Vice President, Novozymes, said, "We are delighted to expand this license agreement with HGS. We license both the fusion protein and the yeast expression systems, which have been optimised for producing albumin fusion proteins as the solution that provides an efficacious half-life in patients. Our strength lies in the fact that we focus on solutions and that is why Novozymes is an ideal partner for the pharmaceutical industry. This enables Novozymes to continue to further develop albufuse®, our proprietary albumin fusion technology, and advance our existing and new partnerships." 5/21/2009Human Genome Reports Positive Results For Long-Term Phase 2 Continuation Trial Of Benlysta In SLE Patients - Update Human Genome Sciences Reveals Positive Trial Results Of Lupus Drug, Shares Up - Update Human Genome Sciences Reveals Positive Long-Term Data For BENLYSTA In Patients With Active Systemic Lupus Erythematosus - Quick Facts Human Genome Sciences - Racing To Cure Lupus Human Genome Sciences Submits Biologics License Application For ABthrax To FDA - (RTTNews) - Thursday, (5-21-09) biotechnology company Human Genome Sciences, Inc. (HGSI: News ) announced the submission of a Biologics License Application or BLA with the U.S. Food and Drug Administration or FDA related to human monoclonal antibody drug Abthrax for the treatment of inhalation anthrax. Anthrax infection is caused by a spore-forming bacterium, Bacillus anthracis, which multiplies in the body and produces lethal toxins. The Rockville, Maryland-based company said the BLA was submitted on the results of the efficacy tests of raxibacumab carried out on rabbits and monkeys. The results exhibited a survival benefit in both rabbits and monkeys, which is needed for launching the efficacy of new drugs used to counter bioterrorism. The submission also includes the results of safety studies of raxibacumab conducted in healthy human volunteers. Raxibacumab is a first-in-class treatment for anthrax, and is being developed under a contract entered into in 2006 with the Biomedical Advanced Research and Development Authority or BARDA. In the first quarter of 2009, under the BARDA contract, HGS achieved its first product sales by initiating the delivery of 20,000 doses of raxibacumab to the U.S. Strategic National Stockpile for emergency use in the treatment of inhalation anthrax. HGS said it generated revenue of $153.8 million in raxibacumab in the first quarter, including $127.8 million in product sales. The company has now completed delivery and expects to recognize at least $8.0 million in additional raxibacumab revenue in the second quarter of 2009. Commenting on the submission, HGS' senior vice president, development and regulatory affairs, Sally Bolmer said, "Based on the results of our efficacy and safety studies, we believe raxibacumab has the potential to be an important new treatment for inhalation anthrax. In addition, the raxibacumab BLA is the first HGS has submitted, so it represents a significant milestone for our company."
RELATED STORY LINKS
Human Genome Shares Rally on Drug Trial At Wall Street Journal, 6/11/2009HGS lupus drug sustained benefits for 4 years 6/11/2009CORRECTED - CORRECTED-UPDATE 2-Human Genome says lupus drug... 6/11/2009UPDATE 3-Human Genome says lupus drug shows positive results 6/11/2009Human Genome Sciences Announces Completion of Enrollment in... 6/19/2009Human Genome Sciences to Host July 20 Conference Call to... 7/1/2009
Human Genome Sciences to Host July 20 Conference Call to Discuss Top-Line Phase 3 Results for Benlysta(TM) (Formerly Lymphostat-B(R)) in Systemic Lupus ErythematosusJuly 1, 2009 7:00 AM ET All PR Newswire news ROCKVILLE, Maryland, July 1 /PRNewswire-USNewswire/ -- Human Genome Sciences, Inc. HGSI today announced that it expects to have top-line results available on Monday, July 20, from BLISS-52, the first of two pivotal Phase 3 clinical trials of BENLYSTA(TM) (belimumab, formerly LymphoStat-B(R)) in systemic lupus erythematosus (SLE). |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |